Toward a world consensus on prevention of schizophrenia by Van Os, Jim & Delespaul, Philippe
he detection of psychotic disorder in the prodromal
phases,coupled with specialized early interventions to pre-
vent transition to overt psychotic disorder,has become the
subject of an increasing amount of research and debate.
1-8
Although this issue is by no means new,
9,10 it is only in the last
few years that the outlines of a consensus,based on quanti-
tative arguments,are becoming discernible.These will be dis-
cussed in this article, using data from several population-
based investigations to illustrate the quantitative arguments.
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Screening for preschizophrenia in the general population with the aim of preventing transition to full-blown illness
is an epidemiological impossibility because a rare disease cannot be predicted. The lack of specificity resulting in abun-
dance of false-positives can be remedied in part by using much more restrictive screening criteria that combine sev-
eral indicators of risk for transition to schizophrenia. Raising the specificity (reducing the false-positives), however, can
only be done at the expense of sensitivity (increasing the false-negatives). The most commonly used strategy to raise
specificity is the sample enrichment strategy. This involves the creation of samples enriched with schizophrenia risk by
selectively filtering at-risk people out over a range of consecutive referral processes starting in the general popula-
tion, through to general practioners, mental health services, and the early detection clinic. However, improvements
in specificity obtained by the sample enrichment strategy should not be attributed to the use of some predictive instru-
ment that supposedly identifies high-risk individuals. The epidemiologically and ethically most viable way for screen-
ing and early detection is to selectively increase the permeability of the filters on the pathway to mental health care.
This will occasion samples of help-seekers enriched with schizophrenia risk at the level of mental health services (thus
reducing false-positives), while at the same time making an attempt to “attract” as many detectable schizophrenia
prodromes as possible through the filters along the pathway to mental health care (thus reducing false-negatives).
Early psychosis research has yielded some useful suggestions in that it is becoming increasingly clear that it is not
just psychosis itself, but rather the clinical context of the psychotic experience that determines risk for transition to
schizophrenia. Thus, risk for transition to full-blown psychotic disorder is to a large degree determined by size of psy-
chosis “load,” comorbid distress and depression, cannabis use, cognitive ability, and subjective reports of impairment
and coping. Making a diagnosis of psychotic disorder is not an exact science: it involves an arbitrary cutoff imposed
on dimensional variation of psychopathology and need for care over time. Gaining insight into the cognitive and bio-
logical factors that drive the dimensional variation, including therapeutic interventions, is arguably more useful than
sterile dichotomous prediction models.  
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prevention in the first place?
The answer to this question is evident.If there is a way
to prevent an illness that usually has a poor prognosis
and starts in young adulthood, every effort should be
made to put preventive measures into place.Work orig-
inating in Germany,the Netherlands,Norway,and else-
where has suggested that a delay of about 1 year between
the onset of positive psychotic symptoms and the initia-
tion of treatment is not rare.
11-13 From the patient’s point
of view this contributes not only to severe social stagna-
tion and decline,
14,15 but also to severe mental suffering,
thus providing a powerful rationale for prompt treatment
immediately after the onset of the first psychotic episode.
Another rationale for rapidly commencing treatment is
the possibility that the longer the duration of untreated
psychosis (DUP),the less effective treatment will be in
the long term.
16,17 It is quite likely that part of the
observed association between a longer DUP and neu-
ropsychological deterioration is noncausal.
18,19 However,
the mere possibility that prolonged episodes of psychosis
impact negatively on longer-term outcome  justifies the
need for increased vigilance on the part of the clinician
to identify prodromal symptoms.
20,21
However, the concept of screening and prevention in
schizophrenia hinges on schizophrenia somehow mani-
festing itself before the onset of the disease.Therefore,
the rationale for schizophrenia prevention,in terms of
feasibility,needs to be demonstrated first.Evidence has
come from two lines of research.The first focused more
on the expression of nonpsychopathological vulnerabil-
ity over the course of development,and the second more
on the expression of subclinical psychotic phenomena
proximal to illness onset (Figure 1).
Research on developmental vulnerabilities long before
onset
The first line of research had its focus on the develop-
mental trajectories of children destined later to develop
schizophrenia,and established that there were small,but
detectable, group differences between the preschizo-
phrenia children and their peers in terms of motor,social,
and cognitive development.
22Although the existence of
such indicators of developmental vulnerability could in
theory be used to initiate a selective prevention program,
it soon became clear that although group differences
were detectable between preschizophrenia children and
their peers as early as 2 years of age, these differences
were very small, with the great majority of preschizo-
phrenia children scoring well within the normal range.
This would make it all but impossible to predict prospec-
tively,on the basis of such developmental indicators,if
a child would develop schizophrenia.
23 For example,if,in
a cohort of 5000 children, 20 children (0.4%) out of a
total of 30 destined to develop schizophrenia have a
value on a motor development variable below 40 on a
scale of 1 to 100,and the children share this feature on
the developmental motor variable with 2000 (40%) other
children in the cohort, it can be readily seen that—
although significant—the predictive value of this score
will be too low for the purpose of screening and preven-
tion.The only way to remedy this situation is to intro-
duce,with the wisdom of hindsight,some post hoc selec-
tion criterion
24 that nevertheless would not have been
available prospectively.
25
Research on mental state vulnerabilities close to onset
The second line of research should not be seen in isola-
tion from the first, but a crucial difference is that the
focus now is not so much on indicators of vulnerability
expressed in parameters of motor, social, or cognitive
development,but on parameters related to mental state
and functioning in the period closer to the onset of the
disorder,which,in the case of an actual illness onset,can
retrospectively be labeled as prodromes of the illness.
Careful follow-back studies of first-episode schizophre-
nia patients using instruments like the Interview for
Retrospective Assessment of Schizophrenia (IRAOS)
26
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Figure 1. Prepsychotic expression of illness.
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ghave established that the great majority of first-episode
patients displayed evidence of signs and symptoms up to
6 years prior to onset of the psychotic disorder.
27 Given
the high rate of detectable prodromes in patients, the
question arises of whether these prodromes could not
have been used to identify individuals in the very early
throes of psychosis,so that early treatment would have
possibly aborted their further transition to full-blown
psychotic disorder.In other words,if it is not possible to
practice selective prevention in the developmental phase,
would it be possible to practice indicated prevention in
the prodromal phases (Figure 2)?
So schizophrenia has detectable prodromes,
but how many—if any—prodrome-like 
mental states exist in the general 
population and must we distinguish 
between prevalence and incidence?
Prevalence of subclinical psychotic experiences
While it may well be possible to diagnose,with the wis-
dom of hindsight,the presence of prodromes in patients
with established disease, the real issue is to try to turn
things around and establish prospectively whether indi-
viduals with mental state experiences that resemble pro-
dromes (if indeed such individuals exist at all in
detectable quantities) will go on to develop schizophre-
nia in the future.From this prospective perspective,pro-
drome-like mental states can best be labeled as subclin-
ical psychotic experiences instead of prodromes, as
prodromes can only be diagnosed a posteriori,after the
onset of the psychotic illness. A crucial question then
becomes what the rate is of such subclinical psychotic
experiences in these populations. We are particularly
interested in subclinical positive psychotic experiences,
as arguably these,in contrast to the very subtle,subclin-
ical expression of experiences resembling negative symp-
toms or formal thought disorder,should also be measur-
able with reasonable accuracy in healthy populations.
Indeed,key variables used in early identification and pre-
vention of psychotic disorder are so-called attenuated,
brief,or limited,psychotic symptoms,as well as schizo-
typal signs and symptoms (Figure 3).
28-35 Recent popula-
tion-based research from the USA, France, the
Netherlands,New Zealand,and Germany suggests that
the lifetime prevalence of such subclinical psychotic
experiences is very high.
35-40 The data collected in the
USA,New Zealand,Germany,and the Netherlands are
summarized together in Table I, as they used similar
instruments across different age-groups and excluded
psychotic phenomena due to drug use and physical ill-
ness.These studies show that the rate of subclinical psy-
chosis is around 10% to 20%,depending on type of psy-
chotic experience and age-group.The prevalence rate of
psychotic experiences associated with distress is consid-
erably lower at around 4%, although this figure is still
much higher than the prevalence of nonaffective psy-
chosis (less than 1%).
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Figure 2. Prevention of full-blown psychotic disorder.
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Figure 3. Course of subclinical psychosis. Person c has a stable low level
and person d a stable higher level of subclinical psychosis.
Persons a and b have unstable levels, but person a never
crosses the clinical threshold, whereas person b does. Person
e has unstable levels, develops an attenuated psychotic expe-
rience that initially resolves, but later results in full-blown psy-
chotic disorder. The psychotic disorder of person e could pos-
sibly have been prevented by intervening in the attenuated
stage. BLIPS, brief limited intermittent psychotic symptoms.
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While the lifetime prevalence of subclinical experiences
is important,the incidence is more relevant from the clin-
ical viewpoint.Thus, trying to predict schizophrenia in
somebody who had a psychotic experience 15 years ago
is clinically less relevant than trying to predict schizo-
phrenia in a person who,a week ago,had first-ever onset
of a subclinical psychotic experience.It is perhaps sur-
prising that,in spite of the fact that schizophrenia pre-
vention is becoming increasingly more topical—even to
the point of including individuals in randomized, con-
trolled trials to prevent transition to full-blown psychotic
disorder—virtually nothing is known about the epidemi-
ological parameters of the mental state phenomena that
are widely used to identify high-risk individuals.Only two
studies, one in the USA
41 and one in Europe,
42 have
attempted to quantify the incidence of psychotic experi-
ences below the level of clinical disorder,both based on
repeated measurements in a large general population
sample.Given the fact that the incidence of schizophre-
nia as a clinical disorder is low at around 0.01% to
0.02%, the results of both studies are, similarly to the
prevalence data shown above, in stark contrast, as the
incidences found were 1% in the American study
41 and
2% in the European study.
42 In other words,the incidence
of subclinical psychosis is about 100 times more frequent
than its clinical counterpart.
What does “transition” from subclinical to clinical
mean?
The high population prevalence and incidence rates of
subclinical psychosis suggest that the psychosis pheno-
type exists in nature in a much more continuous state
than the diagnostic manuals based on patients admitted
to psychiatric hospitals would suggest.
43,44 Early detection
clinics report “high-risk”individuals having 50% transi-
tion rates to “psychotic disorder”
45,46 over a 3- to 6-month
period.However,making a diagnosis of psychotic disor-
der is not an exact science,it involves an arbitrary cutoff
imposed on dimensional variations of psychopathology
and the need for care over time.Gaining insight into the
cognitive and biological factors that drive the dimen-
sional variation,including therapeutic interventions,is
arguably more useful than sterile dichotomous predic-
tion models.
So, if the rate of subclinical psychosis is 
comparatively high, how predictable—if at
all—is the transition to schizophrenia?
The significance of the high prevalence and incidence
rates of subclinical psychotic experiences is that the ratio
of subclinical/clinical is necessarily going to be very high:
about 1:100 for incidence and about 1:20 for prevalence.
In other words,for each 100 new onset cases of subclin-
ical psychosis,only one case of nonaffective psychotic dis-
order is going to result:the predictive value is only 1%.
Similarly, for each 20 individuals who have ever had a
subclinical psychotic experience in their lives,only one is
also going to have a lifetime diagnosis of nonaffective
psychotic disorder: the diagnostic value is only 5%. In
other words,if incident subclinical psychotic experiences
were going to be used as a test to screen for incident psy-
chotic disorder in the general population,99% would be
rated false-positive,and if prevalent subclinical psychotic
experiences were going to be used as a test to screen for
prevalent psychotic disorder,95% would be rated false-
positive.
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Table I. Lifetime prevalences of DIS/CIDI subclinical psychotic experiences expressed in percentages. DIS, Diagnostic Interview Schedule; CIDI, Composite
International Diagnostic Interview.
Country of  No. of  Age  Hallucinations Delusions Hallucinations  Remarks
study patients (years) and delusions
USA
36 810 18-64 11% Rate for two or more 
symptoms was 4.2%
New Zealand
35 761 26 13% 20% –
761 11 – – 14%
Germany
38 2548 17-28 5% 16% 18% Rate for two or more 
symptoms was 7.3%
Netherlands
39 7075 18-64 6% 9% 18% Regardless of presence of distress
7075 18-64 2% 3% 4% With distress/help-seeking behaviorThe diagnostic value and the predictive value of subclin-
ical psychotic experiences in the general population stud-
ies have,until very recently,never been formally tested.
In a European longitudinal, general population study,
Hanssen et al
47 assessed the diagnostic value of subclini-
cal psychotic experiences by quantifying how many indi-
viduals with a lifetime subclinical psychotic experience
also had a lifetime diagnosis of affective or nonaffective
psychotic disorder.They found that the diagnostic value
for any subclinical psychotic experience was 8%.
47 The
same authors assessed the 2-year predictive value of new
onset subclinical psychotic experiences on later new onset
of affective or nonaffective psychotic disorder and found
that this also was 8%—as this was calculated over 2 years
the 1-year predictive value would be 4%.This latter find-
ing was somewhat surprising,as the predictive value of
4% is much higher than the expected 1% described
above.The reason for the discrepancy was that affective
and nonaffective psychotic disorder in this general popu-
lation sample were combined into a single category with
a higher rate than the traditional 0.01% to 0.02% schizo-
phrenia incidence.In addition,the high incidence of psy-
chotic disorder in general population studies,as opposed
to treatment samples,is well known
35,41 and can be taken
to prove that case definition on the basis of treatment
introduces a degree of treatment bias, also known as
Berkson bias,in psychiatric incidence studies.
48 
Given predictive and diagnostic values 
of 4% to 8%, how effective would 
prodromal intervention be if a treatment 
with a 50% success rate existed?
Let us very optimistically assume that,given the 4% pre-
dictive value described above, a treatment existed that
could be applied in the prodromal phase and would abort
transition to full-blown psychotic disorder in 50% of
treated cases.If we wished to apply this treatment on the
basis of a screening program for subclinical psychotic
experiences in the general population,how many people
who screened positive would need to be treated to prevent
one case of psychotic disorder? This can be calculated
quite simply as 0.04 (the predictive value) × 0.5 (the treat-
ment success rate) =0.02 or,in other words,for every 100
cases who screened positive for subclinical psychosis and
received treatment,2 transitions would be prevented.In
other words, the number needed to treat
49 would be 50
and, more importantly, the number needed to inconve-
nience would be 49, ie, 49 individuals would needlessly
receive treatment.Clearly,such figures indicate that early
intervention in the general population is not feasible,at
least not on the basis of the subclinical psychosis screen-
ing criterion.However,even if a screening criterion existed
with a 25% predictive value,the number needed to incon-
venience would still be 7 (Table II)—unacceptably high
given the ethical rules surrounding screening in most coun-
tries
50 and given the fact that antipsychotic treatments may
not be without side effects.
51-53
For screening and prevention of 
schizophrenia, not much can be done 
with predictive and diagnostic values of 
4% to 8%. Can these values be improved?
The conclusion so far has been very simple:it is very dif-
ficult to predict or diagnose a rare disease in the general
population on the basis of a test resembling some pre-
cursor phenomenon. Is it possible to improve on this
state of affairs? The answer to this question is yes,and the
strategy to follow is to change schizophrenia from a rare
disease to a common disease:if instead of 1%,the preva-
lence of schizophrenia were 50%,the predictive value of
any test,even pointing at random to a person with one’s
eyes closed,would be at least 50%,clearly a much more
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Table II. The number of people screening positive for subclinical psychotic experiences who needed to be treated to prevent one case of full-blown psy-
chotic disorder, as a function of the predictive value of the test and the success rate of the prodromal treatment in preventing transition to full-
blown psychotic disorder.
Predictive value (%) Treatment success rate (%) Number needed to treat Number needed to inconvenience
52 5 8 0 7 9
55 0 4 0 3 9
20 25 20 19
20 50 10 9
50 25 8 7
50 50 4 3attractive situation epidemiologically than the 8% prob-
ability reported above.As of course the incidence and
prevalence of schizophrenia cannot be changed, some
indirect manipulation must be employed in order to
make the disease more “predictable.”Below,three pos-
sible strategies will be described.
Raising the rate of schizophrenia by changing the 
context of risk
In the previous sections, the predictive and diagnostic
values of a single predictor,subclinical psychotic experi-
ences,were examined.However,if there are other pre-
dictors,and their effects are additive,the predictive value
will increase accordingly,as illustrated in Figure 4.The
problem with this strategy,however,is that although the
combination of predictors into a single criterion will
make schizophrenia more predictable,it will also apply
to fewer patients (Figure 4).For example,if a family his-
tory of schizophrenia is used as an additional criterion
for prediction, the maximum proportion of all future
schizophrenia patients that can be predicted is 20%,as
only 20% of all patients with schizophrenia have a posi-
tive family history.Therefore, the more predictors one
combines,the greater the probability that a transition to
psychotic disorder is going to take place in the near
future,but also the greater the probability that this is not
relevant for the bulk of schizophrenia cases that one is
trying to prevent from occurring.In the case of a deadly
disease for which a curative treatment existed in the pro-
dromal phase, the strategy of combining predictors to
enhance specificity at the expense of sensitivity would be
disastrous,as one would need to reduce the number of
false-negatives to an absolute minimum.However,in the
case of schizophrenia,it could be argued that,given the
fact that uncertainty exists about the type and effective-
ness of treatments in the prodromal phase,
54 and that the
disease is not rapidly fatal,the goal should be to err on
the side of reduction in false-positives rather than false-
negatives,so as not to unnecessarily burden and/or stig-
matize healthy individuals.
Raising the rate of schizophrenia by changing the
quality of the subclinical psychosis
Although the majority of research efforts in the field of
early identification and prevention made use of the pres-
ence of subclinical psychotic experiences (attenuated,
brief,or otherwise subclinical psychotic experiences) to
predict transition to full-blown psychotic disorder,work
pertaining to the field of cognitive psychology predicts that
the prognosis of subclinical psychosis also depends on
associated features,such as the amount of subclinical psy-
chosis,degree of associated distress,tendency to experi-
ence negative emotions (neuroticism),comorbid depres-
sion,and coping.
55-58
A recent series of publications pertaining to the
Netherlands Mental Health Survey and Incidence Stduy
(NEMESIS) clarified the issue of context of the subclin-
ical psychotic experience in relation to the later onset of
psychotic disorder.In this study,a randomly selected gen-
eral population cohort was interviewed with the
Composite International Diagnostic Interview (CIDI)
59
three times (T0,T1,and T2) over a period of 4 years,and
individuals with suspected psychotic symptomatology
were reinterviewed by clinicians over the telephone.
39,44,60,61
Given the longitudinal design,it was possible to identify
a group of individuals who at T0 were free of any lifetime
clinical or subclinical psychotic experiences and who at
T1 had developed first-onset,incident subclinical  psy-
Clinical research
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Figure 4. Making schizophrenia more predictable (but for fewer
patients). Predictor A is the presence of subclinical psychotic
experiences, which previous research has shown increased the
1-year risk of schizophrenia by 4%. As the majority of patients
with schizophrenia (around 90%) displayed such subclinical
experiences as part of the prodrome, 90% of all schizophrenia
should theoretically be predictable if this criterion were used.
However, if a family history of schiozphrenia were used (pre-
dictor B), only 20% of all schizophrenia would be predictable,
given that only 20% of patients have a family history.
Therefore, although the application of predictor C (the combi-
nation of subclinical psychosis and a positive family history)
greatly increased the 1-year predictive value, only a small pro-
portion of all schizophrenia would be predictable with the cri-
terion.
Predictor A:
subclinical
psychotic
experience
1-year predictive
value: 4%
Proportion of all
schizophrenia
predictable by this
criterion: 90%
Proportion of all
schizophrenia
predictable by this
criterion: 20%
Proportion of all
schizophrenia
predictable by this
criterion: 18%
1-year predictive
value: 0.5%
2-year predictive
value: 25%
Predictor B:
family
history
schizophrenia
Predictor C:
A and B
combinedchotic experiences.The individuals with T1 incident psy-
chosis were subsequently seen again at T2,2 years later,
and assessed for new onset of psychotic disorder. As
reported above,the probability of developing a first-ever
onset of psychotic disorder given the presence of a first-
ever onset of a subclinical psychotic experience 2 years
earlier was 8%.However,this risk could be modified sub-
stantially depending on a range of characteristics associ-
ated with the subclinical experience (Table III).
42 For
example, the number of incident subclinical psychotic
experiences as well as their quality in terms of associated
depression and distress or help-seeking behavior raised
the predictive values considerably up to 500%,as did the
presence of high levels of neuroticism,cannabis use,low
cognitive ability, and subjective reports of impact on
functioning (Table III).
Although these results may seem encouraging, a com-
parison with the data in Table II will make it clear that
even these higher predictive values come nowhere near
an acceptable trade off between successful abortions of
transition to psychotic disorder and numbers needed to
inconvenience.They nevertheless provide valuable clues
to the dynamics of the onset of psychotic disorder,which
may be useful,if not at the level of the general popula-
tion,certainly at the level of mental health care.
Raising the rate of schizophrenia by sample 
enrichment strategies
The sample enrichment strategy basically consists of the
creation of a sample with many people at risk by selec-
tively filtering them out over a range of consecutive
referral processes starting in the general population,
through to general practioners (GPs),mental health ser-
vices,and the early detection clinic.The sample enrich-
ment strategy is undoubtedly the most widely used
approach in the early intervention literature,but possi-
bly also the worst understood,in that the high predictive
values obtained in sample enrichment studies are often
wrongly attributed to some instrument with supposedly
high predictive values,whereas in reality they are a func-
tion of the sample enrichment strategy itself.For exam-
ple,several authors have suggested that the high “transi-
tion rate” to psychotic illness in individuals exhibiting
psychosis-like symptoms is between 40% and 70%,
thanks to the use of some prodromal-rating instru-
ment,
34,45,46,62,63 advocating the use of such instruments in
order to reduce transition to full-blown illness.However,
closer inspection of these data is required,as illustrated
by the following example.
In a recent publication,Klosterkotter et al
63 reported a
follow-up study of 160 young individuals who were con-
sidered to be at risk of developing psychotic illness.The
signs and symptoms used to predict transition to schizo-
phrenia were from a list of “basic symptoms.”
64The pres-
ence of any of the baseline basic symptoms was used as
a test to predict the onset of psychosis over a mean fol-
low-up period of 9.6 years. The main results are pre-
sented in Table IV:the risk of developing schizophrenia,
given the presence of a basic symptom described by
Huber et al,
64 was 77/110 (70%).Therefore, these data
apparently predicted the onset of schizophrenia over a
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Table III. Predictive value of incident subclinical psychotic experiences on incident affective and nonaffective psychotic disorder 2 years later as a func-
tion of associated characteristics of the predictor.
42 CI, confidence interval. *These data were not reported in reference 42, but were analyzed
specially for the purpose of this paper; for methods see reference 42. # A proxy measure of cognitive ability (educational attainment) was
used.
T1 predictor 2-year predictive value  95% CI
for psychotic disorder
Subclinical psychotic experience 8% 6.8-8.4
Subclinical psychotic experience + some degree of distress or help-seeking  14% 14.5-16.8
associated with experience*
Subclinical psychotic experience + depressed mood 15% 13.6-15.8
More than one subclinical psychotic experience 21% 19.8-22.3
More than one subclinical psychotic experience with low mood 40% 38.5-41.5
Subclinical psychotic experience and some degree of subjective impairment of functioning* 16% 14.5-16.8
Subclinical psychotic experience and cannabis use* 13% 11.5-13.5
Subclinical psychotic experience and lower cognitive ability*# 13% 11.5-13.5
Subclinical psychotic experience and high neuroticism* 12% 11-13Clinical research
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9-year period with 70% accuracy! The question,however,
is whether this high predictive accuracy can be com-
pletely attributed to these basic symptoms,or whether
instead other factors are more important.In reality,only
a minor proportion of the predictive value can be attrib-
uted to the basic symptoms, because most can be
ascribed to the very high baseline rate of schizophrenia
in this sample.As can be seen in Table IV,the final rate
of schizophrenia in this sample was 79/160 (49%).The
conclusion from this is that by chance alone,any subject
in this study had a nearly 50% probability of developing
schizophrenia anyway. In other words, the predictive
value of any factor, whether it be basic symptoms, sex,
color of the eyes,or any other random variable,would
have been at least 50%.Thus,the role of the basic symp-
toms was to raise the predictive value modestly from
50% to 70%,not to fully cause a predictive value of 70%.
Instead of the predictive value of basic symptoms, the
real noteworthy element of the remarkable study by
Klosterkotter et al
63 lies in the fact that the authors suc-
ceeded in creating a series of sophisticated selection
processes that led to a final enriched sample of individu-
als with a 50% probability of developing schizophrenia
over the 9.6-year period. This selective enrichment
process involved the existence of special interest groups
at German university psychiatry departments, with an
interest in young people who posed a challenge with
regard to a possible diagnosis of schizophrenia.Such a
center “attracts”a highly enriched sample of individuals
at risk of schizophrenia through a series of selection
processes,as illustrated in Table V.Individuals in the gen-
eral population developing illness behavior visit the GP.
The GP refers those with suspected severe mental disor-
der to the general mental health services.The general
mental health services refer those with suspected schiz-
ophrenia onto the specialist university department.With
each referral from one level to the next, a selection
process takes place creating “enriched”samples that are
progressively more likely to contain individuals who are
likely to develop schizophrenia.Other groups wishing to
replicate the German findings in their own setting,must
therefore not only use the basic symptom scale, but,
much more importantly,replicate exactly the same sam-
ple enrichment strategy to yield a sample with a 50%
probability of developing schizophrenia. In addition,
rather than a posteriori,any additional contribution of
basic symptoms to the predictive value needs to be repli-
cated prospectively in a fresh sample at the start of sam-
pling enrichment procedure.If the results hold after these
replications,the basic symptoms,
64 or instruments used in
Melbourne,Australia,
46 or New Haven,Conn,
45 may pos-
sibly be used to modestly raise the predictive value from
50% to 70% in samples enriched with schizophrenia risk.
In Table V, the effect of using measures such as Basic
Symptoms or other high-risk instruments at other levels
in the sample enrichment procedure with more diluted
samples and therefore lower rates of (future) schizo-
phrenia is shown.The predictive values were calculated
using the DIAGTEST procedure in the STATA statisti-
cal program,version 8,
65 at various levels with their cor-
responding best estimate rates of schizophrenia. The
DIAGTEST procedure in STATA provides the predic-
tive values based on Bayes’ theorem.As can be seen in
Table IV,in the general population,the basic symptoms
would not yield a positive predictive value (PPV) of
70%,but of only 1.4%,and at other levels in the sample
enrichment procedure the predictive values were also
much lower.
Thus,reports of high PPVs in schizophrenia on the basis
of mental states or other risk factors can be attributed to
the high baseline rates of schizophrenia in the samples
used,created through a series of selection procedures in
the sampling process
34,45,46,63 or,sometimes,the statistical
62
procedure used.
25,66These selection procedures contribute
Table IV. Predictive value of basic symptoms of schizophrenia in a 9.6-year
follow-up of 160 young individuals.
63
Outcome Total
Psychosis + Psychosis -
Test Symptom + 77 33 110
Symptom – 24 8 5 0
Total 79 81
Table V. Positive predictive value (PPV) of basic symptoms at different lev-
els along the pathways of mental health care with varying schiz-
ophrenia prevalences. *These figures were reported by
Klosterkotter et al, 2001.
63 In the other rows, the PPV has been
adjusted for the change in prevalence, all else remaining the
same.
Care pathway level Prevalence of  PPV of basic 
schizophrenia symptoms
64
General population 0.6% 1.4%
Primary care 2.0% 4.7%
Mental health outpatients 7.0% 15.3%
Specialized university  50%* 70%*
department with special 
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to exciting and clinically relevant findings. However,
almost invariably a large proportion of the predictive val-
ues are wrongly attributed to the various predictors used
rather than to the selection procedures that resulted in
higher prevalence or incidence rates of schizophrenia
and hence a higher baseline predictive value.The conse-
quence of this confusion is that clinicians attempting to
use such findings in their practice may erroneously focus
on the predictors rather than the sampling enrichment
selection procedure itself.In addition,the high predictive
values reported in the literature are often based on a pos-
teriori optimization algorithms in the sample at the end
of the sample enrichment filtering procedure.The correct
procedure would be to demonstrate its validity a priori
in a prospective investigation at the beginning of the
sample enrichment procedure.
Of course,the sample enrichment strategy,similarly to the
other strategies to raise the prevalence of schizophrenia
that were discussed earlier,suffers from the limitation that
only a tiny proportion of all detectable schizophrenia
cases in the general population will be identified for early
treatment in this way.The great majority of prodromal
schizophrenia will never make it through the various
selection procedures from the decision to visit the GP,
subsequent GP referral to mental health outpatients,and
from there to the specialized prodromal clinic—they will
only come to the attention of mental health services after
having developed the first acute psychotic episode,not
before.Although it is true that prevention of even 1% of
all transitions to schizophrenia would constitute an impor-
tant result from the clinical viewpoint, one may never-
theless question whether specialized early intervention
clinics can ever be made cost-effective,given competing
demands for funding.
67
Do people with preschizophrenia 
wish to be “detected”?
In the previous sections,it was demonstrated that screen-
ing at the level of the general population is not useful
from a methodological viewpoint,as diagnostic and pre-
dictive values would remain too low.However,screening
in the general population may also be ethically unsound
as one may well violate the person’s right “not to know”
that one has (a risk for) a mental illness.This problem
may be overcome by screening individuals who demon-
strate subclinical psychotic experiences at the level of
mental health outpatient services instead of the general
population level.To screen at the mental health services’
level would not only result in much higher predictive val-
ues as seen above,but would have the additional advan-
tage that such individuals would already have acknowl-
edged a need for help for a mental health problem.This
strategy would result in less danger of stigmatization in
the case of a false-positive test result or of violating the
right “not to know” in the case of a true positive test
result. In fact, the only way to go about screening for
schizophrenia in not only a methodologically but also an
ethically responsible fashion, would be to screen for
schizophrenia in individuals who are already seeking
mental health care:the prevalence of schizophrenia in
this population is sufficiently high to make screening fea-
sible and they would already have developed the hypoth-
esis that they may need help for a problem to do with
their mental health.Even then,however,there may be a
risk that,as people become more focused on the culture
of detection and prevention of schizophrenia,the cultural
change itself would result in increasing numbers of peo-
ple receiving (pre)schizophrenia diagnoses,similar to the
recent fashionable reduction in the diagnostic threshold
for attention deficit–hyperactivity disorder (ADHD) and
autism spectrum disorder in children,and multiple per-
sonality disorder in adults.
So far, all we have seen are high-risk 
strategies that may prevent transition 
to full-blown psychotic disorder in a 
tiny proportion of all preventable 
schizophrenia: can’t we do better 
than that?
The prevention paradox
The problem with the high-risk strategies described so
far is what has been called the prevention paradox.
68At
the heart of the paradox lies the observation that pre-
venting a small number transitions to psychotic disorder
is possible without being able to affect transition of the
large number of all other preventable schizophrenia.In
other words,the high-risk groups used for screening and
prevention are not very representative of all preventable
schizophrenia,and focusing on the low-risk groups would
therefore have a much higher preventive yield.
The strategy to focus on everybody at risk,regardless of
whether their risk is high or low, is a form of universal
prevention or population prevention.An example of thistype of intervention is to raise the price of alcoholic bev-
erages to reduce traffic accidents.Raising the prices of
alcohol reduces alcohol consumption in the whole pop-
ulation.Raising prices therefore affects not only the few
problem drinkers,who are most at risk for traffic acci-
dents,but also the much more prevalent group of mod-
erate drinkers.Although the problem drinkers are more
at risk of traffic accidents than the moderate drinkers,
most alcohol-related accidents are not caused by the few
problem drinkers,but by the much more prevalent group
of moderate drinkers,whose individual risk may be lower
than the problem drinkers,but whose impact on the total
population rate of traffic accidents is higher simply
because there are many more moderate drinkers than
problem drinkers.
In the field of schizophrenia,the analogy with the alcohol
paradigm lies in increasing the permeability of the “filters
along the pathway to mental health care.”
69These “filters”
refer to the hurdles that a prospective patient,with a newly
developed psychotic illness,will encounter before coming
into contact with a qualified mental health professional
(Figure 5).The first filter on the pathway to mental health
care is the development of awareness on the part of the
patient and his or her family and friends that there are psy-
chotic experiences resulting in behavior necessitating con-
sultation with a health professional,who is usually the GP.
The next filter is the ability of the GP to detect the early
symptoms of psychotic illness,resulting in an accurate pro-
visional diagnosis.The next filter comprises the GP’s deci-
sion to refer the patient to the appropriate mental health
services.Once in contact with the services,many patients
with psychotic illness will pass the filter and move on to
the next level,which is admission to hospital.If the per-
meability of the filters can be increased,the whole popu-
lation,regardless of whether their risk for psychosis is high
or low, will experience a greater accessibility to mental
health services and therefore to the possibility of schizo-
phrenia prevention.
How the permeability of these filters can be influenced
was demonstrated in a Norwegian study.
70,71 In this study,
an extensive public information campaign was conducted
to educate the general population, schools, and health
professionals alike, regarding the signs and symptoms
associated with early psychosis and the long-term bene-
fits of early referral,diagnosis,and treatment.An obser-
vation of this study was that,compared with the period
prior to the campaign,the incidence of reported psychotic
illness increased to approximately 40% with an associated
reduction in the time taken for initiation of treatment or
DUP,
70,71 suggesting that the campaign had caused a rela-
tively large increase in the permeability of the filters along
the mental health care pathway.Similar improvements in
mental health care have also been corroborated by an
Australian study
72 and a Canadian study.
73The significance
of these studies was to demonstrate that the filters could
be made more permeable so that more early psychosis
came earlier in contact with services.
The great advantage of the universal prevention
approach is that it will make people come to mental
health services rather than the other way round,reduc-
ing the inherent risk of stigmatization and falsely label-
ing individuals.Another advantage is that previous work
has shown that individuals whose subjective subclinical
experiences are not objectively recognized by the clini-
cian nevertheless have a higher risk of transition to psy-
chotic disorder
74—under the universal prevention strat-
egy these individuals can also be encouraged to seek help
at the level of mental health care more easily.However,
the cost-effectiveness of these public health campaigns
and the extent to which the patients referred were in the
throws of a brief psychotic state that would have resolved
naturally anyway remains to be elucidated.Another risk
with this approach is that services will become flooded
by individuals with all types of mental health complaints,
many of which are not in need of treatment, let alone
treatment in the context of schizophrenia prevention.
Clinical research
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Figure 5. Filter model of psychotic symptoms and psychotic disorder. GP,
general practitioner.
Reproduced from reference 69: Goldberg D, Huxley P. Mental Illness
in the Community. London, UK: Tavistock Publications; 1980. Copyright
© Tavistock Publications, 1980.
1. General population
2. Population attending GP
3. GP recognized
4. Mental health outpatients
5. Psychiatric hospital
Filter 4:
Psychiatric 
referral
Filter 3:
GP referral
Filter 3:
GP recognition
Filter 3:
Illness
behaviorA more restrictive campaign approach would be to tar-
get general practices only.Bak and colleagues
75 described
a much more limited information campaign among GPs
who were offered a possibility of rapid, low-threshold
referral service for patients with early psychosis in an
urban setting.These authors also reported an increase in
referrals compared with the precampaign period.
Another more restrictive approach would be to combine
the universal with the high-risk sample enrichment strat-
egy by making the filters more permeable,while at the
same time putting restrictions into place so that only
those who are most likely to carry schizophrenia risk
would rise more easily through the filters on the pathway
to mental health care and come into contact with a spe-
cialized early intervention clinic.This could be done,for
example,by focusing community educational campaigns
very restrictively on psychosis and its prodromes.
If rare disorders are so difficult to predict,
why not make the process more efficient 
and use subclinical psychosis to predict 
psychotic disorders and also the much 
more prevalent nonpsychotic disorders?
The NEMESIS study demonstrated that the predictive
value of subclinical psychotic experiences remains low
even if affective and nonaffective psychotic disorders are
combined into a single outcome category because of lack
of specificity.
42 However,this very lack of specificity may
be an advantage in public health terms, as it raises the
possibility of strategies to predict and prevent a range of
psychiatric disorders,not just schizophrenia.
76Thus,the
predictive efficiency of subclinical psychosis may be
enhanced considerably if it used to not only predict psy-
chotic disorder,but also a range of other disorders such
as depression and anxiety, which, according to recent
research, are also moderately strongly comorbid with
psychosis.
77,78 Using the three interview waves (T0,T1,
and T2) of the NEMESIS data discussed above,we cal-
culated the predictive value of first-ever onset subclini-
cal psychotic experiences at T1 on T2 incidence of
Diagnostic and Statistical Manual of Mental Disorders,
Third Edition,Revised (DSM-III-R) depressive disorder,
anxiety disorder,alcohol or drug misuse,and any nonpsy-
chotic disorder,alone and in combination with T2 inci-
dent affective and nonaffective psychotic disorder.This
revealed that predictive values for nonpsychotic disorder
were lower than the 8% predictive value for psychotic
disorder, with the exception of depression (predictive
value:13%).Combining psychotic and nonpsychotic dis-
order outcome categories only raised predictive values
by a small amount (Table VI).
Conclusion
The area of early intervention and prevention of psy-
chotic illness is certainly exciting and brings a much-
needed focus to the underfunded mental health services
for the severely mentally ill.On the other hand,a range
of epidemiological and ethical issues remain to be
addressed.Similarly,it has been pointed out that early
detection and good early treatment need to go hand in
hand,
5 and unfortunately the evidence base for so-called
phase-specific treatments at this time remains very lim-
ited,offering little guidance.
54 Lastly,cost-effectiveness
data remain wanting.Therefore, the following conclu-
sions can be drawn:
• Early detection clinics report “high-risk” individuals
having 50% transition rates to “psychotic disorder”
over a 3- to 6-month period.However,making a diag-
nosis of psychotic disorder is not an exact science: it
involves an arbitrary cutoff imposed on dimensional
variations of psychopathology and the need for care
over time.Gaining insight into the cognitive and bio-
logical factors that drive the dimensional variation,
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Table VI. Predictive values, using the three waves of the Netherlands
Mental Health Survey and Incidence Study (NEMESIS) (T0, T1,
and T2) of T1 incident subclinical psychotic experiences on T2
incident disorders. CI, confidence interval.
T2 predicted outcome Predictive value of T1 
incident subclinical 
psychotic experiences 
(95% CI)
Psychotic disorder 8% (6.8, 8.4)
Depressive disorder 13% (11.6, 13.9)
Anxiety disorder 4% (3.7, 5.0)
Alcohol/drug misuse disorder 6% (5.4, 7.1)
Any nonpsychotic disorder 7% (5.5, 7.4)
Combined depressive disorder  15% (13.8, 16.0)
and psychotic disorder
Combined anxiety disorder  9% (7.6, 9.4)
and psychotic disorder
Alcohol/drug misuse disorder  10% (8.7, 10.5)
and psychotic disorder
Any disorder 7% (5.5, 7.4)including therapeutic interventions,is arguably more
useful than sterile dichotomous prediction models.
• Screening in the general population for at-risk mental
states is useless: a rare disease such as schizophrenia
cannot be predicted using prevalent predictors.In fact,
depressive disorder can be better predicted by subclin-
ical psychotic experiences than psychotic disorder itself
(although for depression the predictive value also
remains much too low to be useful for screening pur-
poses).
• Screening predictive values can be improved substan-
tially by manipulating the sample rate of (future) schiz-
ophrenia,but the price to be paid is high as large num-
bers of false-negatives will be created, which will
remain permanently “undetectable.” The sample
enrichment strategy (creating samples with many peo-
ple at risk by selectively filtering them out over a range
of consecutive referral processes starting in the general
population,through to GPs,mental health services,and
the early detection clinic) is the most commonly used
strategy to improve screening predictive values, but
these improvements are equally commonly wrongly
attributed to the use of some predictive instrument that
supposedly identifies high-risk individuals.
• If one considers that cost-effectiveness considerations
should not stand in the way of clinicians attempting to
help people at risk of making the transition to psychotic
disorder, the epidemiologically and ethically most
viable way for screening and early detection is to selec-
tively increase the permeability of the filters on the
pathway to mental health care.This will occasion sam-
ples of help-seekers enriched with schizophrenia risk at
the level of mental health services (reduction of false-
positive rate), while at the same time making an
attempt to “attract”as many detectable schizophrenia
prodromes as possible through the filters along the
pathway to mental health care (reduction of false-neg-
ative rate).
•Although the feasibility,usefulness,and cost-effective-
ness of screening and early detection remains uncer-
tain,clinicians continue to be regularly faced with the
difficult decision of whether or not to treat an early
psychosis–like state. Research in early psychosis has
yielded some useful suggestions in that it is becoming
increasingly clear that not just psychosis by itself,but
rather the clinical context of the psychotic experience
determines risk for transition to schizophrenia.Thus,
risk for transition to full-blown psychotic disorder is to
a large degree predicted by size of psychosis “load,”
comorbid distress and depression,cannabis use,cogni-
tive ability,and subjective reports of impairment and
coping. ❏
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Hacia un consenso mundial sobre la prevención de la esquizofrenia
La selección de sujetos pre-esquizofrénicos en la población general con el objetivo de prevenir la transición
hacia la enfermedad totalmente constituída constituye una imposibilidad epidemiológica dado que una enfer-
medad poco frecuente no se puede predecir. La falta de especificidad, que da origen a gran cantidad de fal-
sos positivos, puede ser remediada en parte al utilizar criterios de selección mucho más restrictivos que com-
binen algunos indicadores de riesgo para la transición hacia la esquizofrenia. Sin embargo, el aumento de la
especificidad (reducción de falsos positivos) sólo puede realizarse a expensas de la sensibilidad (aumento de
falsos negativos). La estrategia más comúnmente utilizada para aumentar la especificidad es el enriqueci-
miento de la muestra. Esta implica la creación de muestras enriquecidas con pacientes con riesgo de esqui-
zofrenia mediante la filtración selectiva de sujetos con riesgo a partir de una serie de procesos de deriva-
ción consecutiva que se inician en la población general, a través de médicos generales, servicios de salud mental
y clínicas para la detección precoz. Sin embargo, un aumento en la especificidad obtenido mediante la estra-
tegia de enriquecimiento de la muestra no debe ser atribuido al empleo de algún instrumento predictor que
presuntamente identifique individuos con alto riesgo. La forma de selección y detección precoz epidemio-
lógica y éticamente más viable, es el aumento selectivo de la permeabilidad de los filtros en el camino hacia
la atención en salud mental. Esto generará muestras de buscadores de ayuda enriquecidas con pacientes con
riesgo de esquizofrenia a nivel de los servicios de salud mental  (reduciendo así los falsos positivos) y al mismo
tiempo se intentará “atraer” en cuanto sea posible a pacientes con pródromos esquizofrénicos detectables
mediante filtros a lo largo del camino hacia la atención en salud mental (reduciendo así los falsos negativos).
La investigación en psicosis precoces ha entregado algunas sugerencias útiles que están siendo cada vez más
claras en el sentido que no sólo la psicosis en sí misma, sino que el contexto clínico de la experiencia psicótica
es el que determina el riesgo de la transición hacia la esquizofrenia. De este modo, el riesgo de transición
hacia el trastorno psicótico totalmente constituído está determinado en gran medida por el peso de la “carga”
psicótica, el distrés y la depresión comórbidos, el empleo de cannabis, la capacidad cognitiva y las expresio-
nes subjetivas de deterioro y adaptación. La realización del diagnóstico de un trastorno psicótico no consti-
tuye una ciencia exacta, sino que implica la imposición de un límite arbitrario a las variaciones en las dimen-
siones psicopatológicas y la necesidad de evaluación a lo largo del tiempo. El progreso en la comprensión de
los factores cognitivos y biológicos que llevan a la variación de las dimensiones, incluyendo las intervenciones
terapéuticas, es discutiblemente más útil que los estériles modelos de predicción dicotómica.  36. Eaton WW, Romanoski A, Anthony JC, Nestadt G. Screening for psy-
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Vers un consensus mondial sur la prévention de la schizophrénie
Le dépistage d’état préschizophrénique dans la population générale dans le but d’empêcher le passage à
la forme déclarée de la maladie est une impossibilité épidémiologique, parce qu’une maladie rare ne peut
être anticipée. Le manque de spécificité dû à l’abondance des faux positifs peut être compensé en partie
par des critères de dépistage plus restrictifs associant plusieurs indicateurs de risque pour le passage à la
schizophrénie. L’augmentation de la spécificité (réduction des faux positifs) ne peut néanmoins se faire
qu’aux dépens de la sensibilité (augmentation des faux négatifs). La méthode la plus répandue pour aug-
menter la spécificité est d’enrichir l’échantillon. Cela implique la création d’échantillons dans lesquels le
risque schizophrénique est augmenté en filtrant sélectivement les individus à risque par une série d’orien-
tations successives à partir de la population générale en passant par les médecins généralistes, les services
de santé mentale et les services de détection clinique précoce. Néanmoins, ces améliorations de spécificité
obtenues par cette méthode ne devraient pas être attribuées à l’utilisation de quelques instruments pré-
dictifs supposés identifier les patients à haut risque. La méthode de dépistage et de détection précoce qui
a le plus de chances de réussir épidémiologiquement et éthiquement est d’augmenter sélectivement la per-
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